Alvotech SA (ALVO)
ICEX 
Summary
ALVO Chart
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
Alvotech maintains at a Hold rating due to missed H1 2026 earnings and ongoing regulatory challenges, despite pipeline progress. Recent FDA CRLs for AVT05 and AVT06 were due to manufacturing issues, now addressed, with BLAs resubmitted and multiple approvals targeted for Q4 2026. AVT06, a biosimilar to EYLEA, has global commercialization rights secured post-November 2026, with patent disputes resolved and a large market opportunity.
Alvotech Q2 Earnings Call Highlights
Alvotech NASDAQ: ALVO said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed full-year revenue and adjusted EBITDA guidance and highlighted upcoming regulatory decisions and product launches.
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates
Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.14 per share a year ago.
Alvotech SA (ALVO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alvotech SA ever had a stock split?
Alvotech SA Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Lisa Graver CEO | ICEX Exchange | LU2458332611 ISIN |
| LU Country | 1,279 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Alvotech, a prominent entity specialized in the development and manufacturing of biosimilar medicines, serves a global patient base through its various subsidiaries. Founded in 2013 and headquartered in Luxembourg, Luxembourg, Alvotech aims to make therapeutic solutions more accessible and affordable in areas including autoimmune diseases, eye conditions, bone disorders, and cancer treatment. By offering biosimilar products, Alvotech contributes to expanding treatment options and improving patient outcomes across a wide spectrum of medical conditions.
Products and Services
AVT02: A high-concentration formulation biosimilar to Humira, targeting a range of inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis among others. This lead program indicates Alvotech’s commitment to addressing widespread autoimmune conditions.
AVT04: A biosimilar to Stelara, focused on treating a variety of inflammatory conditions including psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. This demonstrates the company's endeavor to provide alternatives in the management of chronic inflammatory conditions.
AVT06: A biosimilar to Eylea, aimed at treating conditions such as age-related macular degeneration, macular edema, and diabetic retinopathy. This product underlines Alvotech’s efforts in combating eye diseases that can lead to severe vision impairment or blindness.
AVT03: Currently in the pre-clinical phase, this biosimilar to Xgeva and Prolia is being developed to prevent bone fractures, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as to prevent bone loss and increase bone mass. It shows Alvotech’s initiative towards addressing the skeletal impacts of cancer.
AVT05: An early phase development project, this biosimilar to Simponi and Simponi Aria focuses on various inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, among others. This extends the company's portfolio into additional autoimmune disease treatments.
AVT16: A biosimilar to an Entyvio product, reinforcing Alvotech's presence in the segment of gastrointestinal disorder treatments, highlighting the ongoing research towards new therapeutic solutions.
AVT23: A late-stage development biosimilar to Xolair, targeting the treatment of nasal polyps. This product represents the company's expansion into treatments for respiratory and allergic conditions.
AVT33: A biosimilar to a Keytruda product, focusing on cancer treatment. By developing a biosimilar to one of the leading immunotherapies for cancer, Alvotech is marking its entry into the oncology biosimilar market, demonstrating its dedication to offering more accessible cancer care options.
